Registry for adults with confirmed digestive neuroendocrine tumors
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This is a registry study that collects medical information from adults with neuroendocrine tumors (NETs) that start in the digestive organs. It helps researchers understand these cancers better and may support future studies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- Your NET diagnosis is confirmed by tissue/cell testing or a Gallium-68 PET scan plus a CT or MRI scan
- Your diagnosis of a digestive NET was made within 1 year before you sign consent
- Your tumor is graded as G1, G2, or G3 (based on WHO 2019 rules)
- The tumor started in the digestive tract (or its starting point is unknown)
- You agree to take part by signing informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies treatments for young adults (ages 18-39) with cancers of the digestive system or neuroendocrine tumors. It aims to find better ways to help this age group, no matter the cancer stage or grade.
This study looks at how tumor and patient factors affect treatment response in well-differentiated GEP-NENs (neuroendocrine tumors of the digestive system). It may help doctors understand which treatments work best for people like you.
This is a research registry that collects information from adults with suspected or diagnosed pancreatic cancer. It may help doctors better understand the disease and improve care over time.
This trial looks at epigenomic markers in different types of neuroendocrine tumors and cancers to find better ways to diagnose and treat them. It may help if you have a neuroendocrine tumor or certain other gastrointestinal cancers that can be surgically removed or biopsied.
This trial studies a new way to classify and predict outcomes for people with a specific type of neuroendocrine tumor (NET G3). It uses tumor tissue and past scans to better understand your cancer and guide treatment.
This study follows people with a type of tumor called a neuroendocrine tumor (NET) that started in the digestive system or lungs, to learn more about how the disease progresses and how it responds to treatment.
Hear when a new Gastro-entero Pancreatic Neuroendocrine Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.